@article{CJCR2295,
author = {Chengrong Lu and Jianzeng Zhao and Xiaoping Wang and li Liu},
title = {ELEMENTAL STUDY OF GENE THERAPY WITH THROMBOPOIETIN},
journal = {Chinese Journal of Cancer Research},
volume = {9},
number = {3},
year = {2013},
keywords = {},
abstract = {Thrombopoietin (TPO) is also referred to as the c-mpl ligand or megakaryocyte growth and development factor, inducing thrombopoiesis by proliferation of megakaryocyte progenitors and promoting endoreplicatton of mature megakaryocytes, t The identification of TPO, and the demonstration that administration to normal experimental animals with recombinant TPO results in a marked increase in platelets count, 2 has opened the possibility of using TPO to rescue patients from life-threatening thrombocytopenia with high dose chemotherapy and radiotherapy. But recombinant TPO is a foreign protein and has adverse effects on patients to different extent. This study is to establish a new TPO administration by gene therapeutic methods, i.e. that after transferred into animals, the TPO gene expresses functional TPO in vivo and maintains high platelet level.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/2295}
}